GABA Therapeutics Completed Phase 1 Etifoxine in Melbourne

GABA Therapeutics has continued to progress the development of GRX-917 without any material impact from the COVID-19 pandemic. GABA Therapeutics recently completed its Phase 1 clinical trial of the anxiolytic etifoxine in Melbourne, Australia, on time and slightly ahead of budget. The two-stage, double-blind, placebo-controlled single and multiple dose [...]

Biotech with Anxiety Drug Lands Funding

DRUGS: $15.5M; XANAX IMPROVEMENT? Biotech with Anxiety Drug Lands Funding By Jessie Yount Orange Country Business Journal Monday, February 24, 2020 An effort to develop a new and improved version of an anti-anxiety drug—never commercialized in the U.S.—is underway in Newport Beach. Gaba Therapeutics Inc. has developed and patented a [...]

GABA Therapeutics Commences Phase I Study in Etifoxine – Melbourne Australia

Today, GABA Therapeutics commenced dosing for its Phase I clinical trial of the anxiolytic etifoxine in Melbourne, Australia – right on schedule. The Phase I, two-stage, double-blind, placebo-controlled single and multiple dose study will evaluate the pharmacokinetics, pharmacodynamics, and safety of oral etifoxine in up to 34 normal healthy [...]

GABA Therapeutics Receives Approval to Begin Phase I Clinical Trials

We are pleased to provide some positive updates. Inaugural Board Meeting The company held its first Board of Directors meeting in San Francisco in early November. Attendees included (left to right): Srini Rao M.D., Ph.D, Chief Medical Officer, GABA Therapeutics Ian Massey, D.Phil, CEO and Director, GABA Therapeutics Richard [...]

GABA Therapeutics and ATAI Life Sciences Partner to Develop a Novel GABA Modulator for the Treatment of Mood Disorders

NEWPORT BEACH, Calif. and BERLIN, Sept. 20, 2019 /PRNewswire/ -- Today, GABA Therapeutics, a biotech company focused on the treatment of mood disorders, and ATAI Life Sciences, a global biotech company builder working on paradigm shifting interventions for unmet needs in the mental health space, announced a partnership to develop a novel compound that promises [...]